Linagliptin Viatris: Uses, Dosage & Side Effects
A DPP-4 inhibitor for the treatment of type 2 diabetes mellitus in adults, used to improve blood sugar control alongside diet and exercise
Linagliptin Viatris is a prescription oral medication containing linagliptin 5 mg, a dipeptidyl peptidase-4 (DPP-4) inhibitor used for the treatment of type 2 diabetes mellitus in adults. It works by blocking the DPP-4 enzyme, which increases the levels of active incretin hormones (GLP-1 and GIP) that stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner. Linagliptin Viatris is taken once daily with or without food, requires no dose adjustment for kidney or liver impairment, and has a low risk of hypoglycemia when used as monotherapy or in combination with metformin. It is a generic equivalent of the originator product Trajenta, manufactured by Viatris to the same quality standards.
Quick Facts: Linagliptin Viatris
Key Takeaways
- Linagliptin Viatris contains linagliptin 5 mg, a DPP-4 inhibitor that lowers blood sugar in a glucose-dependent manner, resulting in a low risk of hypoglycemia when used alone or with metformin.
- Taken once daily as a single 5 mg tablet with or without food – no dose adjustment is needed for patients with any degree of kidney impairment, a unique advantage among DPP-4 inhibitors.
- Can be used as monotherapy (when metformin is not tolerated) or in combination with metformin, sulfonylureas, pioglitazone, or insulin for flexible diabetes management.
- The CARMELINA and CAROLINA cardiovascular outcomes trials confirmed cardiovascular safety, demonstrating no increased risk of major cardiovascular events compared with placebo or glimepiride.
- Generally well tolerated with common side effects limited to nasopharyngitis and cough; rare but important risks include pancreatitis and bullous pemphigoid which require prompt medical attention.
What Is Linagliptin Viatris and What Is It Used For?
Linagliptin Viatris contains the active substance linagliptin, a potent, selective, and reversible inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). This medication belongs to a class of antidiabetic drugs known as DPP-4 inhibitors or gliptins, which have become an established part of the treatment landscape for type 2 diabetes mellitus since the first member of the class was approved in 2006. Linagliptin Viatris is a generic formulation manufactured by Viatris, bioequivalent to the originator product Trajenta (marketed by Boehringer Ingelheim), meaning it delivers the same amount of active drug to the body and is therapeutically interchangeable.
Type 2 diabetes mellitus is a chronic metabolic disorder characterized by insulin resistance and progressive beta-cell dysfunction, leading to elevated blood glucose levels (hyperglycemia). Over time, uncontrolled hyperglycemia damages blood vessels and nerves, increasing the risk of serious complications including cardiovascular disease, kidney disease (diabetic nephropathy), eye damage (diabetic retinopathy), and nerve damage (diabetic neuropathy). Effective blood sugar control is therefore essential to reduce the risk of these complications and improve long-term health outcomes. The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommend an individualized approach to diabetes management, with pharmacological therapy tailored to each patient’s clinical profile, comorbidities, and preferences.
The incretin system plays a central role in glucose homeostasis. After eating, the gastrointestinal tract releases incretin hormones, primarily glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones stimulate insulin secretion from pancreatic beta cells and suppress glucagon release from alpha cells, both in a glucose-dependent manner – meaning their effects are strongest when blood sugar is elevated and diminish as blood sugar normalizes. This glucose-dependent mechanism is clinically important because it means that DPP-4 inhibitors carry a very low risk of causing hypoglycemia (dangerously low blood sugar) when used alone or in combination with metformin.
Under normal physiological conditions, GLP-1 and GIP are rapidly degraded by the enzyme DPP-4, with a half-life of only 1–2 minutes. By inhibiting DPP-4, linagliptin prevents this rapid degradation, effectively doubling or tripling the circulating levels of active GLP-1 and GIP. This enhanced incretin activity leads to increased meal-stimulated insulin secretion, reduced postprandial glucagon levels, and consequently lower blood glucose levels both after meals (postprandial) and in the fasting state. The net result is a clinically meaningful reduction in HbA1c (glycated hemoglobin), the standard marker of long-term blood sugar control.
Linagliptin Viatris is indicated for the treatment of type 2 diabetes mellitus in adults, in the following clinical situations:
- Monotherapy: When diet and exercise alone do not provide adequate blood sugar control, and when metformin is inappropriate due to intolerance or contraindications (such as severe kidney disease).
- Dual combination therapy: In combination with metformin, when metformin alone (with diet and exercise) does not provide adequate glycemic control.
- Dual combination with sulfonylurea: In combination with a sulfonylurea (such as glimepiride) and diet/exercise, when metformin is inappropriate.
- Triple combination therapy: In combination with metformin plus a sulfonylurea, or metformin plus pioglitazone, when dual therapy does not achieve target blood sugar levels.
- Add-on to insulin: In combination with insulin (with or without metformin), when insulin alone does not provide adequate glycemic control.
Clinical trials have consistently demonstrated that linagliptin reduces HbA1c by approximately 0.5–0.7% from baseline when added to diet and exercise alone, metformin, or other background therapies. While this reduction may appear modest compared with some other antidiabetic classes, it is clinically significant and is achieved with a favorable safety profile, including a very low risk of hypoglycemia and weight neutrality (linagliptin does not cause weight gain). These characteristics make linagliptin a valuable option particularly for patients who are at increased risk of hypoglycemia (such as elderly patients) or those who wish to avoid weight gain associated with other diabetes medications.
Unlike most other DPP-4 inhibitors (such as sitagliptin, saxagliptin, and alogliptin), linagliptin is primarily eliminated through the bile and gastrointestinal tract rather than the kidneys. More than 80% of an oral dose is excreted unchanged in the feces, with only about 5% eliminated renally. This unique elimination pathway means that no dose adjustment is required for patients with any degree of kidney impairment, including those on dialysis – a significant practical advantage for the many type 2 diabetes patients who also have chronic kidney disease.
What Should You Know Before Taking Linagliptin Viatris?
Contraindications
The primary contraindication to Linagliptin Viatris is hypersensitivity (allergy) to linagliptin or to any of the excipients in the formulation. The inactive ingredients include mannitol, pregelatinized starch (maize), maize starch, copovidone, magnesium stearate, and the film coating components hypromellose, titanium dioxide (E171), talc, macrogol 6000, and iron oxide red (E172). If you have a known allergy to any of these substances, you must not take this medication.
Serious hypersensitivity reactions have been reported in post-marketing experience with linagliptin-containing products, including anaphylaxis, angioedema (swelling of the face, lips, tongue, or throat), and exfoliative skin conditions. These reactions typically occur within the first 3 months of treatment, with some reports after the first dose. If you experience signs of a severe allergic reaction, discontinue Linagliptin Viatris immediately and seek emergency medical attention.
Warnings and Precautions
Cases of acute pancreatitis have been reported in patients taking DPP-4 inhibitors, including linagliptin. If you experience severe, persistent abdominal pain that may radiate to your back, with or without nausea and vomiting, stop taking Linagliptin Viatris and contact your doctor immediately. If pancreatitis is confirmed, treatment must not be restarted. Linagliptin should not be used in patients with a history of pancreatitis.
Before starting Linagliptin Viatris, discuss the following with your healthcare provider:
- Pancreatitis: DPP-4 inhibitors as a class have been associated with rare cases of acute pancreatitis. Patients should be informed of the characteristic symptoms (persistent, severe abdominal pain). If pancreatitis is suspected, linagliptin should be discontinued. Linagliptin has not been studied in patients with a history of pancreatitis, and it is unknown whether these patients are at increased risk.
- Hypoglycemia risk with sulfonylureas or insulin: When linagliptin is used in combination with a sulfonylurea (such as glimepiride or glibenclamide) or insulin, the risk of hypoglycemia is increased. Your doctor may need to reduce the dose of the sulfonylurea or insulin when adding linagliptin to minimize this risk. Recognize the symptoms of hypoglycemia: sweating, shakiness, rapid heartbeat, dizziness, hunger, confusion, and blurred vision.
- Bullous pemphigoid: Cases of bullous pemphigoid, an autoimmune blistering skin condition, have been reported with DPP-4 inhibitors including linagliptin. If you develop blisters or erosions on the skin, particularly in areas such as the trunk, limbs, or oral mucosa, stop the medication and consult your doctor. Treatment with linagliptin should not be restarted if bullous pemphigoid is confirmed.
- Heart failure: The CARMELINA trial included patients with heart failure (NYHA class I–III). While no overall increase in heart failure hospitalization was observed, clinical experience with linagliptin in patients with NYHA class IV heart failure is limited. Use with caution in this population.
- Type 1 diabetes or diabetic ketoacidosis: Linagliptin Viatris is not appropriate for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. It should not be used as a substitute for insulin in insulin-requiring patients.
Pregnancy and Breastfeeding
Linagliptin Viatris should not be used during pregnancy. There are no adequate clinical data on the use of linagliptin in pregnant women. Animal studies have not shown direct harmful effects on fertility, pregnancy, embryonal/fetal development, or postnatal development at clinically relevant doses. However, as a precaution, linagliptin should be avoided during pregnancy. If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor. During pregnancy, diabetes should generally be managed with insulin to maintain adequate blood sugar control.
It is not known whether linagliptin is excreted in human breast milk. Animal studies have shown that linagliptin and its metabolites are secreted in milk. A risk to the breastfed infant cannot be excluded. The decision to continue or discontinue breastfeeding or to continue or discontinue Linagliptin Viatris therapy should be made in consultation with your doctor, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother.
Driving and Operating Machinery
Linagliptin Viatris has no or negligible influence on the ability to drive and use machines. However, when used in combination with sulfonylureas or insulin, patients should be counseled about the risk of hypoglycemia, which can impair concentration and reaction time. If you experience symptoms of low blood sugar while taking Linagliptin Viatris, do not drive or operate machinery until the symptoms have resolved.
How Does Linagliptin Viatris Interact with Other Drugs?
Linagliptin has a favorable drug interaction profile compared with many other oral diabetes medications. It is a substrate of the cytochrome P450 enzyme CYP3A4 and the efflux transporter P-glycoprotein (P-gp), but it is a weak competitive inhibitor and not an inducer of these systems. This means that linagliptin is unlikely to affect the metabolism of other drugs to a clinically meaningful extent.
In vitro and in vivo pharmacokinetic studies have systematically evaluated the potential for drug interactions with linagliptin. The following table summarizes the key findings from these assessments:
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Rifampicin | Reduces linagliptin exposure by ~40% (CYP3A4/P-gp induction) | May reduce efficacy; combination not recommended |
| Ritonavir | Increases linagliptin exposure by ~2-fold (CYP3A4/P-gp inhibition) | No dose adjustment needed; not clinically significant |
| Metformin | No pharmacokinetic interaction | Safe combination; commonly prescribed together |
| Sulfonylureas (e.g., glimepiride) | No pharmacokinetic interaction; pharmacodynamic synergy | Increased hypoglycemia risk; may need SU dose reduction |
| Insulin | No pharmacokinetic interaction; pharmacodynamic synergy | Increased hypoglycemia risk; may need insulin dose reduction |
| Pioglitazone | No pharmacokinetic interaction | Safe combination; no dose adjustment needed |
| Warfarin | No effect on INR or warfarin pharmacokinetics | Safe combination; no dose adjustment needed |
| Digoxin | No clinically relevant interaction | Safe combination; no dose adjustment needed |
| Oral contraceptives | No effect on ethinylestradiol or levonorgestrel levels | Safe combination; no dose adjustment needed |
The most clinically relevant interaction is with rifampicin, a strong inducer of CYP3A4 and P-glycoprotein. Co-administration of rifampicin with linagliptin reduced the steady-state AUC (area under the curve, a measure of total drug exposure) of linagliptin by approximately 40% and the peak plasma concentration by approximately 44%. This reduction may lead to decreased DPP-4 inhibition and potentially reduced efficacy of linagliptin. Based on these findings, the concurrent use of linagliptin with rifampicin or other strong P-gp/CYP3A4 inducers (such as carbamazepine, phenobarbital, or phenytoin) is not recommended. If such a combination is necessary, your doctor should consider an alternative antidiabetic agent that is not affected by these inducers.
Conversely, strong CYP3A4 inhibitors such as ritonavir increase linagliptin exposure approximately 2-fold. However, this increase has not been associated with any clinically meaningful change in the safety or tolerability profile, and no dose adjustment is required when linagliptin is co-administered with strong CYP3A4 inhibitors. This is because linagliptin achieves near-complete DPP-4 inhibition at the 5 mg therapeutic dose, so higher drug exposure does not translate to substantially greater pharmacological effect.
As noted above, the combination of linagliptin with sulfonylureas or insulin requires particular clinical attention. While there is no pharmacokinetic interaction (the drugs do not affect each other’s blood levels), the pharmacodynamic combination of enhanced incretin signaling from linagliptin plus the insulin-secretory or insulin-supplementing effects of sulfonylureas or insulin can lead to additive blood sugar lowering and an increased risk of hypoglycemia. Your doctor may proactively reduce the dose of the sulfonylurea or insulin when initiating linagliptin therapy.
Always inform your doctor, pharmacist, or nurse about all medications you are currently taking, including prescription drugs, over-the-counter medications, herbal supplements, and vitamins. While linagliptin has a relatively low interaction potential, comprehensive medication review helps ensure safe and effective diabetes management.
What Is the Correct Dosage of Linagliptin Viatris?
Linagliptin Viatris has one of the simplest dosing regimens among oral diabetes medications. The recommended dose is 5 mg once daily, and this dose remains the same regardless of the patient’s kidney function, liver function, age, or body weight. This simplicity is a significant clinical advantage, as it reduces the potential for dosing errors, simplifies prescribing, and eliminates the need for laboratory monitoring to guide dose adjustments.
Adults
| Patient Group | Dose | Frequency | Notes |
|---|---|---|---|
| Adults (general) | 5 mg | Once daily | With or without food |
| With metformin | 5 mg | Once daily | Maintain current metformin dose |
| With sulfonylurea | 5 mg | Once daily | Consider lower SU dose to reduce hypoglycemia |
| With insulin | 5 mg | Once daily | Consider lower insulin dose to reduce hypoglycemia |
| Kidney impairment (any stage) | 5 mg | Once daily | No dose adjustment needed |
| Liver impairment | 5 mg | Once daily | No dose adjustment needed |
Take the tablet at approximately the same time each day to help you remember. The tablet should be swallowed whole with a glass of water. It can be taken at any time of day, regardless of meals. If you find it helpful, you may associate the dose with a specific daily routine, such as breakfast or bedtime.
Children and Adolescents
Linagliptin Viatris is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of linagliptin have not been established in this age group. Type 2 diabetes in children and adolescents is managed differently, and healthcare providers should consider age-appropriate alternatives such as metformin or insulin.
Elderly Patients
No dose adjustment is required for elderly patients. Clinical trials of linagliptin included patients aged 65 years and older, including a substantial proportion aged 75 years and older. No overall differences in safety or efficacy were observed between older and younger patients. Linagliptin is particularly well suited for elderly patients with type 2 diabetes because of its low risk of hypoglycemia (when used without sulfonylureas or insulin), weight neutrality, and the absence of the need for dose adjustment based on kidney function, which commonly declines with age.
Missed Dose
If you forget to take a dose of Linagliptin Viatris, take it as soon as you remember on the same day. If you do not remember until the next day, skip the missed dose and take your next dose at the usual time. Do not take a double dose (two tablets in one day) to make up for a forgotten dose. If you miss several consecutive doses, contact your doctor for advice on how to resume treatment and whether your blood sugar should be checked more frequently.
Overdose
In clinical trials, single doses of up to 600 mg (120 times the recommended dose) were administered to healthy volunteers and were generally well tolerated. There is no specific antidote for linagliptin overdose. If an overdose occurs, supportive measures should be instituted as warranted by the patient’s clinical status. Linagliptin is not meaningfully removed by hemodialysis or peritoneal dialysis because of its extensive protein and tissue binding. In the event of a suspected overdose, contact your local poison control center or seek emergency medical care.
What Are the Side Effects of Linagliptin Viatris?
Like all medicines, Linagliptin Viatris can cause side effects, although not everyone who takes it will experience them. The safety profile of linagliptin has been extensively studied in clinical trials involving more than 10,000 patients treated with linagliptin, as well as through ongoing post-marketing pharmacovigilance. In the pivotal clinical trials, the overall incidence of adverse events with linagliptin was comparable to placebo when used as monotherapy or in combination with metformin. The discontinuation rate due to adverse events was also similar between linagliptin and placebo groups (approximately 2–4%).
The CARMELINA cardiovascular outcomes trial (6,979 patients followed for a median of 2.2 years) and the CAROLINA cardiovascular outcomes trial (6,033 patients followed for a median of 6.3 years) provided extensive long-term safety data for linagliptin. CARMELINA demonstrated that linagliptin did not increase the risk of major adverse cardiovascular events (MACE), hospitalization for heart failure, or kidney outcomes compared with placebo in a high-risk population. CAROLINA showed that linagliptin was non-inferior to glimepiride (a sulfonylurea) for cardiovascular safety, with significantly fewer hypoglycemic events.
Common
May affect up to 1 in 10 people
- Nasopharyngitis (common cold, runny nose, sore throat)
- Cough
- Hypoglycemia (when combined with sulfonylureas or insulin)
Uncommon
May affect up to 1 in 100 people
- Diarrhea
- Abdominal pain
- Skin rash
- Pruritus (itching)
- Urticaria (hives)
- Lipase increased (elevated pancreatic enzyme levels)
Rare
May affect up to 1 in 1,000 people
- Pancreatitis (inflammation of the pancreas – severe abdominal pain radiating to the back)
- Bullous pemphigoid (autoimmune skin blistering)
- Angioedema (swelling of the face, lips, tongue, or throat)
Not Known
Frequency cannot be estimated from available data
- Severe hypersensitivity reactions (anaphylaxis)
- Mouth ulceration (oral mucosa ulceration)
- Exfoliative skin conditions
In the monotherapy and metformin combination clinical trials, hypoglycemia occurred with similar frequency in linagliptin and placebo groups (less than 1% of patients), reflecting the glucose-dependent mechanism of action. However, when linagliptin was added to sulfonylurea therapy, the incidence of hypoglycemia was approximately 15–23%, compared with 7–15% with placebo plus sulfonylurea. Similarly, when added to insulin, hypoglycemia rates were higher with linagliptin (22–31%) compared with placebo plus insulin (15–23%). This underscores the importance of proactively reducing the dose of sulfonylureas or insulin when starting linagliptin.
Pancreatitis is a rare but potentially serious adverse event associated with DPP-4 inhibitors as a class. In the CARMELINA trial, the incidence of adjudicated acute pancreatitis was 0.3% with linagliptin versus 0.1% with placebo over a median follow-up of 2.2 years. While the absolute risk is very low, patients should be counseled to report any severe, persistent abdominal pain to their doctor immediately. If pancreatitis is confirmed, linagliptin must be permanently discontinued.
Bullous pemphigoid is a rare autoimmune blistering skin condition that has been reported with DPP-4 inhibitors, including linagliptin. Post-marketing reports suggest that bullous pemphigoid typically develops weeks to months after starting treatment. If large, fluid-filled blisters develop on the skin, treatment should be discontinued and dermatological evaluation obtained. Bullous pemphigoid generally resolves after discontinuation of the causative drug, though it may require topical or systemic corticosteroid treatment.
Contact your doctor immediately if you experience: severe, persistent abdominal pain (possible pancreatitis), large blisters on the skin (possible bullous pemphigoid), swelling of the face, lips, tongue or throat (possible angioedema), or difficulty breathing. If your blood sugar drops too low and you feel confused, extremely drowsy, or lose consciousness, this is a medical emergency.
How Should You Store Linagliptin Viatris?
Proper storage of Linagliptin Viatris is important to maintain the quality, safety, and efficacy of the medication throughout its shelf life. Unlike biological products such as monoclonal antibodies, linagliptin is a small-molecule drug that is relatively stable under normal storage conditions, making it convenient for home storage.
Follow these storage guidelines:
- Temperature: Store below 30°C (86°F). Normal room temperature is acceptable. Do not expose the tablets to excessive heat or direct sunlight.
- Moisture protection: Keep the tablets in the original blister pack until you are ready to take a dose. The blister packaging is designed to protect the tablets from moisture, which can affect their stability. Do not transfer the tablets to a separate pill organizer for extended periods if the storage conditions are humid.
- Keep out of reach of children: Store the medication in a safe location where children and pets cannot access it.
- Expiration date: Do not use Linagliptin Viatris after the expiration date printed on the blister and outer carton after “EXP.” The expiration date refers to the last day of that month.
- Inspection: Before taking a tablet, check that the blister is intact and undamaged. Do not take a tablet if the blister seal has been broken before you open it.
- Disposal: Do not throw unused or expired medications in the household waste or flush them down the toilet. Return unused medicines to your pharmacy for safe disposal according to local regulations. This helps protect the environment from pharmaceutical contamination.
When traveling, keep Linagliptin Viatris in your hand luggage in the original packaging. Avoid storing the medication in a car glove compartment or other locations where temperatures may exceed 30°C. If you are traveling across time zones, continue to take one tablet every 24 hours; minor variations in the exact timing of the dose are not clinically significant.
What Does Linagliptin Viatris Contain?
Understanding the composition of your medication is important, particularly if you have known allergies or intolerances to specific pharmaceutical excipients. Below is a detailed breakdown of the contents of Linagliptin Viatris 5 mg film-coated tablets.
Active Ingredient
The active substance is linagliptin, present at a dose of 5 mg per film-coated tablet. Linagliptin is a xanthine-based molecule (chemically: 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione) with the molecular formula C25H28N8O2 and molecular weight of 472.54 g/mol.
Inactive Ingredients (Excipients)
| Ingredient | Role | Notes |
|---|---|---|
| Linagliptin | Active substance (DPP-4 inhibitor) | 5 mg per tablet |
| Mannitol (E421) | Diluent / filler | Provides tablet bulk |
| Pregelatinized starch (maize) | Binder / disintegrant | Aids tablet formation and dissolution |
| Maize starch | Disintegrant | Promotes tablet break-up in the stomach |
| Copovidone | Binder | Holds tablet together |
| Magnesium stearate | Lubricant | Prevents tablet sticking during manufacturing |
| Hypromellose | Film coating agent | Provides protective film coat |
| Titanium dioxide (E171) | Colorant / opacifier | Gives white base color |
| Talc | Glidant | Improves coating smoothness |
| Macrogol 6000 | Plasticizer | Maintains film coat flexibility |
| Iron oxide red (E172) | Colorant | Gives light pink/red tint |
Appearance and Pack Sizes
Linagliptin Viatris 5 mg tablets are light pink, round, film-coated tablets. They are supplied in blister packs. Available pack sizes may vary by country and may include packs of 10, 14, 28, 30, 56, 60, 84, 90, 98, or 100 film-coated tablets. Not all pack sizes may be marketed in every country.
Marketing Authorization and Manufacturer
Linagliptin Viatris is manufactured and marketed by Viatris, a global healthcare company formed from the combination of Mylan and Upjohn (a Pfizer division). The originator product (Trajenta) is marketed by Boehringer Ingelheim in many countries and by Eli Lilly in others. Linagliptin Viatris has been authorized as a generic medicine based on demonstrated bioequivalence to the reference product.
Frequently Asked Questions About Linagliptin Viatris
Linagliptin Viatris is used to treat type 2 diabetes mellitus in adults. It contains linagliptin, a DPP-4 inhibitor that helps the body produce more insulin and less glucagon after meals, thereby lowering blood sugar levels. It can be used alone (when metformin is not suitable) or in combination with other diabetes medications such as metformin, sulfonylureas, pioglitazone, or insulin. It is always used alongside a healthy diet and regular physical activity. Linagliptin Viatris is not suitable for type 1 diabetes or for treating diabetic ketoacidosis.
Linagliptin Viatris is a generic version of Trajenta. Both products contain the same active ingredient (linagliptin 5 mg) and have been shown to be bioequivalent through rigorous pharmacokinetic studies. This means they deliver the same amount of drug to the bloodstream at the same rate, and there is no clinically meaningful difference in their efficacy or safety. Generic medicines must meet the same regulatory quality standards as the original brand-name products. The main difference is that Linagliptin Viatris is manufactured by Viatris, while Trajenta is manufactured by Boehringer Ingelheim.
No. One of the key advantages of linagliptin is that no dose adjustment is required for any degree of kidney impairment, including patients on dialysis. Unlike most other DPP-4 inhibitors (sitagliptin, saxagliptin, alogliptin), which are primarily eliminated by the kidneys and require dose reductions in patients with reduced kidney function, linagliptin is mainly eliminated through the bile and gut. This makes it an especially suitable choice for the many type 2 diabetes patients who also have chronic kidney disease. The dose remains 5 mg once daily regardless of kidney function.
Acute pancreatitis is a rare but recognized side effect of DPP-4 inhibitors, including linagliptin. In the large CARMELINA cardiovascular outcomes trial, the incidence was 0.3% with linagliptin versus 0.1% with placebo over a median of 2.2 years. While the absolute risk is very low, you should be aware of the symptoms: severe, persistent abdominal pain that may radiate to the back, often accompanied by nausea and vomiting. If you experience these symptoms, stop taking Linagliptin Viatris and seek immediate medical attention. If pancreatitis is confirmed, the medication must not be restarted.
Yes, linagliptin has demonstrated cardiovascular safety in two large, long-term cardiovascular outcomes trials. The CARMELINA trial showed that linagliptin did not increase the risk of major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) compared with placebo in patients with type 2 diabetes at high cardiovascular and kidney risk. The CAROLINA trial further demonstrated that linagliptin was non-inferior to glimepiride (a sulfonylurea) for cardiovascular outcomes over a median follow-up of 6.3 years, while causing significantly fewer episodes of hypoglycemia. Neither trial showed an increased risk of hospitalization for heart failure with linagliptin.
Yes, linagliptin and metformin is one of the most common and well-studied combinations for type 2 diabetes. No pharmacokinetic interaction exists between the two drugs, and they work through complementary mechanisms: metformin reduces hepatic glucose production and improves insulin sensitivity, while linagliptin enhances incretin-mediated insulin secretion and glucagon suppression. The combination provides greater HbA1c reduction than either drug alone. The risk of hypoglycemia with this combination remains very low. Your doctor will determine the appropriate metformin dose based on your individual clinical profile.
References
- European Medicines Agency (EMA). Trajenta (linagliptin) – Summary of Product Characteristics. Last updated 2025. Available at: EMA Trajenta EPAR.
- U.S. Food and Drug Administration (FDA). Tradjenta (linagliptin) – Prescribing Information. Boehringer Ingelheim / Eli Lilly. Revised 2024.
- Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69–79. doi:10.1001/jama.2018.18269.
- Rosenstock J, Kahn SE, Johansen OE, et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA. 2019;322(12):1155–1166. doi:10.1001/jama.2019.13772.
- American Diabetes Association (ADA). Standards of Care in Diabetes – 2025. Diabetes Care. 2025;48(Suppl 1):S1–S352.
- Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–2786. doi:10.2337/dci22-0034.
- Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011;13(3):258–267.
- Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab. 2011;13(10):939–946.
- World Health Organization (WHO). Global Report on Diabetes. 2024. Available at: WHO Diabetes Report.
- British National Formulary (BNF). Linagliptin. National Institute for Health and Care Excellence (NICE). 2025.
About Our Medical Team
All content on iMedic is created and reviewed by qualified medical professionals following international evidence-based guidelines. Our editorial process ensures accuracy, currency, and clinical relevance.
Medical Content Team
Specialists in endocrinology, diabetology, and clinical pharmacology with extensive experience in diabetes management and incretin-based therapies.
Medical Review Board
Independent panel of board-certified physicians who verify all medical claims against current evidence and international guidelines (WHO, EMA, FDA, ADA, EASD).
Editorial Standards
All content follows the GRADE evidence framework and is based on Level 1A evidence from systematic reviews and randomized controlled trials where available.
Independence
iMedic receives no pharmaceutical company funding or sponsorship. All content is editorially independent, ensuring unbiased medical information for patients and caregivers.